

## THINLINE, LLC

**Contact:** William P. Purcell, Ph.D.

**Location:** Memphis, TN, USA

**Email:** [purcell@moleculardesign.com](mailto:purcell@moleculardesign.com)

**Tel:** 901.529.1919

**Website:** <http://www.moleculardesign.com>



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
National Institutes of Health



National Institutes of Health Commercialization Assistance Program  
(NIH-CAP)

## Company Profile

**Industry Sector:** Pharmaceuticals

**Company Overview:** THINLINE is a drug discovery company with a preclinical drug candidate for the treatment of obesity and diabetes. Our proprietary  $\beta_3$  adrenoceptor agonist technology, "FMP 825", is protected by 4 issued US patents with foreign patents pending.

The scientific team includes the company Founder and Chairman, Dr. Purcell who pioneered computer-aided drug design, Dr. Miller, co-inventor/renowned medicinal chemist, and Dr. Feller, co-inventor and award-winning pharmacologist.

THINLINE seeks \$2 million to conduct obese baboon model studies, the next step in development.

THINLINE's Founder has a successful track record of six licensing deals, has secured an LOI, and anticipates another successful licensing deal after the obese baboon model is completed.

**Target Market(s):** Our customers are Pharmaceutical companies seeking pre-clinical lead candidates in treating obesity and diabetes. Patients with obesity and diabetes indications.

## Key Value Drivers

**Technology:** The THINLINE drug candidate is a  $\beta_3$  adrenoceptor agonist which burns fat metabolically for reduction of weight in obesity and helps insulin work through fatty acid oxidation in the treatment of diabetes..

**Competitive Advantage:** Our drug candidate, "FMP 825" exceeds benchmark criteria along all key properties for an effective and safe drug.

**Plan & Strategy:** Raise 2 mil, exit via license post baboon model study..

\*Technology funded by the NIH and being commercialized under the NIH-CAP.

Key Property	Target	FMP 825	Significance
Potency	1 nM	0.5 nM	Exceeds target
Selectivity:	No significant b1 or b2	Not significant	Selectivity Achieved
Oral bioavailability:	30%	51%	Exceeds target
Safety:	No Cardio, CNS or other Toxic Side Effects	No side effects	Safety target Achieved

## Management

### Leadership:

William P. Purcell, Ph.D. Founder and Chairman

Over 30 years of pharmaceutical experience in drug discovery. Successful in closing six licensing deals. Four LLC's spun out of MDI as standalone companies with proprietary technology. Capable and experienced to repeat the process with the current drug candidate.

Grady Garrison, Esq., Intellectual Property and Contracts

Successful IP attorney with proven track record in multiple successful start-up companies.

### Key Scientists:

William P. Purcell, Ph.D. QSAR, Molecular Modeling, Physical Chemistry

Dennis Feller, Ph.D. Director of Pharmacology

Duane Miller, Ph.D. Director of Medicinal Chemistry

## Product Pipeline



Licensing Deal Close

